Setting a new standard for the treatment of chronic inflammation. Press Releases Catch up on the latest news from Evommune. April 26, 2023 Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases October 3, 2022 Evommune Announces Appointment of Dr. Jeegar Patel as Chief Scientific Officer June 27, 2022 Evommune Announces Appointment of Greg Moss as Chief Corporate Strategy and Legal Officer March 22, 2022 Evommune Announces Appointment of Kyle Carver as Chief Financial Officer November 16, 2021 Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases September 9, 2021 Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline January 7, 2021 Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and Company January 5, 2021 Evommune to Present at 2021 Virtual Dermatology Summit November 18, 2020 Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases 12 We have a range of chronic inflammatory disease programs currently in development. See Our Pipeline
